logo

Compugen Ltd (CGEN)



Trade CGEN now with
  Date
  Headline
7/28/2021 7:27:31 AM Compugen Q2 Loss/shr $0.11 Vs. Loss/shr $0.08 Last Year
7/19/2021 7:03:57 AM Compugen Doses First Patient In Phase 1/2 Triple Combination Cohort Expansion Of COM701 With Opdivo And BMS-986207
7/15/2021 7:05:11 AM Compugen Doses First Patient In Phase 1 Combination Study Of COM902 And COM701 In Advanced Malignancies
6/30/2021 7:23:29 AM Compugen Doses First Patient In COM701/Opdivo Phase 1b Cohort Expansion Study
6/8/2021 7:23:31 AM Compugen Announces Updated Data From Phase 1 Study Of COM701 At ASCO 2021 Annual Meeting
5/13/2021 7:22:13 AM Compugen Q1 Net Loss $9.9 Mln Or $0.12/Shr Vs Loss Of $7.1 Mln Or $0.10/Shr Last Year
4/27/2021 7:51:52 AM Compugen's Preclinical Data Shows Therapeutic Potential Of COM902 In Cancer Immunology, Immunotherapy
12/23/2020 7:03:29 AM Compugen Announces First Milestone In License Deal With AstraZeneca On Bispecific, Multi-specific Antibody Products
11/5/2020 7:07:55 AM Compugen Q3 Net Loss $7.8 Mln Or $0.09/shr Vs. Net Loss $6.5 Mln Or $0.10/shr Last Year
9/30/2020 7:18:54 AM Compugen Announces Addition Of Nils Lonberg To Scientific Advisory Board
9/8/2020 7:08:24 AM Compugen Doses First Patient In Phase 1/2 Triple Combination Study Of COM701 With Opdivo And Anti-TIGIT Antibody
8/28/2020 7:05:42 AM Compugen Says USPTO Granted A New Patent Covering The Composition Of Matter Of COM902
7/30/2020 7:26:40 AM Compugen Q2 Net Loss $6.2 Mln Or $0.08/shr Vs Net Loss $6.0 Mln Or $0.10/shr Last Year
7/30/2020 7:00:00 AM Compugen Reports Second Quarter 2020 Results (Press Release)